A correction may be in store for Inozyme Pharma Inc. (NASDAQ:INZY) shares?

As of close of business last night, Inozyme Pharma Inc.’s stock clocked out at $1.55, up 4.73% from its previous closing price of $1.48. In other words, the price has increased by $+0.0700 from its previous closing price. On the day, 448688 shares were traded. INZY stock price reached its highest trading level at $1.6063 during the session, while it also had its lowest trading level at $1.5050.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report



To gain a deeper understanding of INZY’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.10 and its Current Ratio is at 11.10. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on May 26, 2022, initiated with a Hold rating and assigned the stock a target price of $5.

On February 07, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $33.

On November 29, 2021, Needham started tracking the stock assigning a Buy rating and target price of $23.Needham initiated its Buy rating on November 29, 2021, with a $23 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 19 when Pivotal bioVenture Partners Fu bought 1,070,000 shares for $3.69 per share. The transaction valued at 3,948,300 led to the insider holds 2,661,154 shares of the business.

Subramanian Sanjay bought 27,100 shares of INZY for $99,999 on Apr 19. The SVP, CFO now owns 27,100 shares after completing the transaction at $3.69 per share. On Apr 19, another insider, Hopfner Robert Lorne, who serves as the Director of the company, bought 1,070,000 shares for $3.69 each. As a result, the insider paid 3,948,300 and bolstered with 2,661,154 shares of the company.

Stock Price History:

Over the past 52 weeks, INZY has reached a high of $9.27, while it has fallen to a 52-week low of $1.45. The 50-Day Moving Average of the stock is 2.2716, while the 200-Day Moving Average is calculated to be 3.8699.

Shares Statistics:

It appears that INZY traded 66.77K shares on average per day over the past three months and 61.97k shares per day over the past ten days. A total of 43.66M shares are outstanding, with a floating share count of 39.82M. Insiders hold about 0.90% of the company’s shares, while institutions hold 86.70% stake in the company. Shares short for INZY as of Oct 13, 2022 were 174.79k with a Short Ratio of 0.17M, compared to 182.91k on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 0.44% and a Short% of Float of 0.65%.

Earnings Estimates

As of right now, 7 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.43 for the current quarter, with a high estimate of -$0.4 and a low estimate of -$0.48, while EPS last year was -$0.6. The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.25 and low estimates of -$0.59.

Analysts are recommending an EPS of between -$1.52 and -$2.08 for the fiscal current year, implying an average EPS of -$1.85. EPS for the following year is -$1.85, with 7 analysts recommending between -$1.19 and -$2.42.